Aberrant signaling through the Wnt/b-catenin pathway is a critical determinant in human and rodent liver carcinogenesis and generally accepted to be a potent driver of proliferation. Xenobiotic agonists of the constitutive androstane receptor (CAR) induce massive acute hyperplasia of mouse liver and facilitate the outgrowth of hepatocellular carcinomas with activated b-catenin. In the present study, the interplay of b-catenin-dependent and CAR-dependent signaling in the liver and its effect on hepatocyte proliferation were analyzed in transgenic mice with hepatocytespecific knockout of Ctnnb1 (encoding b-catenin) following treatment with two CAR agonists, 1,4-bis[2-(3,5-dichloropyridyloxy)]-benzene (TCPOBOP) and phenobarbital. Hepatocyte-specific knockout of b-catenin inhibited CAR agonists-induced hepatocyte proliferation in male mice. By contrast, the proliferative effect of CAR agonists was strongly augmented in female b-catenin knockout animals. This was due to prolonged proliferation of the knockout hepatocytes. CAR-mediated hepatocyte proliferation was, at least in part, dependent on estrogen signaling and was associated with enhanced expression of FoxM1 and elevated activity of the PDK1/p90RSK pathway. In conclusion, our study shows that gender-specific factors determine whether b-catenin signaling plays a pro-or an antiproliferative role in the regulation of mouse hepatocyte proliferation induced by CAR agonists.
Exposure to xenobiotics provokes an induction of hepatic drug-metabolizing enzymes which catalyze the biotransformation of the respective compounds. This is regulated by several xenobiotic-sensing receptors which bind different classes of foreign substances and co-ordinate the transcription of particular subsets of drug-metabolizing enzymes, for review, see Xu et al. (2005) .
The xenobiotic-sensing constitutive androstane receptor (CAR) is well characterized with respect to downstream targets related to drug and energy metabolism, as reviewed by Ueda et al. (2002) .
Apart from this, CAR-dependent signaling elicits hepatocyte hyperplasia, as reviewed by Costa et al. (2005) . Moreover, CAR activators promote rodent hepatocarcinogenesis, for review, see Lee (2000) .
CAR mediates the effects of structurally unrelated activators (Kodama and Negishi, 2006) , such as phenobarbital (PB), which acts by a still not fully understood indirect mechanism, or TCPOBOP (1,4-bis[2-(3,5-dichloropyridyloxy)]-benzene), a direct agonist of the receptor (Kelley et al., 1985; Swales and Negishi, 2004) . Interestingly, androgens impede CAR-dependent transcription in male mice (Forman et al., 1998) , whereas estrogens and the estrogen receptor play a more complex role, dependent on the availability and type of ligand and the cellular context (Kawamoto et al., 2000; Makinen et al., 2003; Min, 2010) . Thus, it is not surprising that sex differences exist with regard to CAR-mediated induction of drug-metabolizing enzymes (Braeuning et al., 2009; Hernandez et al., 2009 ) and proliferation (Ledda-Columbano et al., 2003) . Proliferative signaling downstream of CAR involves the induction of c-myc, and its downstream target FoxM1 (Blanco-Bose et al., 2008) and Cyclins (Columbano et al., 1997; Ledda-Columbano et al., 2000) .
Wnt/b-catenin signaling is generally considered a potent driver of hepatocyte proliferation: Its loss results in a delay of liver regeneration after partial hepatectomy (Sekine et al., 2007; Tan et al., 2006) , whereas aberrant b-catenin activation is frequently observed in hepatocellular malignancies, for review, see Takigawa and Brown (2008) . Physiological b-catenin activation regulates liver organogenesis (Nejak-Bowen and Monga, 2008) and hepatic zonation (Benhamouche et al., 2006; Braeuning and Schwarz, 2010; Hailfinger et al., 2006) . Interestingly, b-catenin activation is specifically observed in perivenous hepatocytes (Benhamouche et al., 2006; Sekine et al., 2007) , which, however, proliferate less than their periportal counterparts (Gebhardt, 1988) . Why b-catenin activation leads either to induction (tumors, liver regeneration) or inhibition (perivenous hepatocytes) of proliferation remains unclear.
The aim of the present study was to analyze the role of b-catenin in CAR-mediated hepatocyte proliferation in male and female mice with hepatocyte-specific knockout of Ctnnb1 (encoding b-catenin).
MATERIALS AND METHODS
Animal experiments. Hepatocyte-specific knockout of b-catenin has been described recently (Braeuning et al., 2009) : Tg(albCre) mice expressing Cre recombinase under the control of the hepatocyte-specific albumin promoter (The Jackson Laboratory, Bar Harbor, ME) were interbred with transgenic mice with loxP sites inserted in the introns flanking exons 3 and 6 of Ctnnb1 (Huelsken et al., 2001) , for genotyping primers, see Supplementary Table 1. Eight-week-old mice (five per group; six to seven per group in antiandrogen/ antiestrogen experiments) were treated as schematically depicted in Figure 1 : a single ip-injected dose of 3 mg/kg body weight TCPOBOP (dissolved in corn oil; Sigma, Taufkirchen, Germany) 72 h prior to killing (Fig. 1A) , a single ipinjected dose of 90 mg/kg body weight PB (in PBS; Geyer, Renningen, Germany) 72 h prior to killing, followed by 72 h on PB-containing diet (0.05% wt/vol; Ssniff, Soest, Germany) (Fig. 1B) . During these experiments, mice received 5-bromo-2-deoxyuridine (BrdU; Sigma) via the drinking water (1 mg/ml; prepared fresh daily). In another experiment, mice were treated with TCPOBOP as indicated above and sacrificed after 24, 48, or 72 h, and BrdU was injected ip (1 mg per mouse; in PBS) 24 h prior to killing (Fig. 1C) . To analyze interference with sex hormone signaling, female mice were given two ip injections of the antiestrogen Fulvestrant (in corn oil; Sigma), each 1 mg per animal, 24 h prior to and 24 h after TCPOBOP injection, respectively. Male mice received two ip injections of the antiandrogen Flutamide (in corn oil; Sigma) at the same time points, each 2 mg per animal (Fig. 1D ). In the latter experiments, mice also received BrdU via the drinking water. The total volume per injection was always between 100 and 200 ll. Controls received solvent (Flutamide/Fulvestrant/ TCPOBOP: corn oil; PB: PBS). None of the treatment regimens induced overt signs of toxicity, neither in wild-type (WT) nor in KO mice. Mice were kept on a 12-h dark/light cycle, had access to food and tap water ad libitum, received humane care, and protocols were followed according to the institutional guidelines. Mice were killed between 9 and 11 A.M. to avoid circadian influences. Livers were excised immediately, weighed, and frozen in liquid nitrogen. For immunohistochemistry, aliquots were fixed in Carnoy's fixative and embedded in paraffin.
Quantitative real-time PCR. RNA isolation, reverse transcription, and realtime PCR on a LightCycler (Roche, Mannheim, Germany) were performed as recently described (Braeuning et al., 2009) , for PCR primers, see Supplementary  Table 1 . The 18s rRNA expression was used for normalization. Relative expression of target genes was computed based on the crossing point difference of a sample versus a control and its real-time PCR efficiency according to Pfaffl (2001) .
Immunohistochemistry. Slices from paraffin-embedded livers (5-lm thickness) were stained as recently described using the primary antibodies given in Supplementary Table 2 in combination with appropriate horseradish peroxidase-conjugated secondary antibodies with 3-amino-9-ethylcarbazole/H 2 O 2 as substrates. Nuclei were counterstained by hematoxylin. Slices were blinded prior to evaluation of BrdU and Ki-67 labeling under a light microscope, and labeling indices were determined by two different operators to avoid bias.
Reverse-phase protein microarray. Protein expression profiling was performed using reverse-phase protein microarray (RPA) on the ZeptoMARK assay platform (Zeptosens, Witterswil, Switzerland) . Frozen liver tissue was grinded using a ball mill (Mikro-Dismembrator U; Sartorius, Goettingen, Germany). Tissue lysates were generated under denaturing conditions by adding a 10-fold excess (vol/wt) of CeLyA Lysis Buffer CLB1 (Zeptosens). The prepared lysates were used to produce RPAs as described in detail by Pirnia et al. (2009) ; for generation of the microarrays, an array layout was chosen that uses four replicates of each sample at a protein concentration of 0.4 mg/ml.
Detection of proteins and protein modifications was performed using a direct two-step immunoassay using specific primary antibodies (for information on the used antibodies, see Supplementary Table 2). Fluorescence signal was generated using Alexa647-labeled anti-species secondary antibodies (Invitrogen, Darmstadt, Germany); details on the assay procedure are found in Pirnia et al. (2009) . Images of the microarrays were taken using the ZeptoREADER microarray imager (Zeptosens), and image analysis was performed using the ZeptoVIEW Pro 2.0 software package (Zeptosens). Signal intensity for each spot was determined as background-corrected mean intensity with the local background subtracted from the spot intensity; the determined values were referenced against adjacent reference spots as implemented in the software package giving referenced fluorescence intensity. Background correction was performed (Pirnia et al., 2009) Western blotting. Protein detection was carried out using the primary antibodies listed in Supplementary Table 2. Horseradish peroxidase-conjugated secondary antibodies (blots in Figs. 2 and 3; Santa Cruz Biotechnology, Santa Cruz, CA) or fluorescent-conjugated secondary antibodies (blots in Fig. 5 ; LI-COR Biosciences, Lincoln, NE) were used for signal generation. Fluorescence detection was performed by Odyssey Infrared Imaging System (LI-COR Biosciences). Densitometry was performed using TINA 2.09a software (Raytest, Straubenhardt, Germany).
Statistical analysis. Nonparametric statistical analysis of microarray data was performed using Wilcoxon rank-sum test (R, Version 2.4.0; http:// www.r-project.org). For cluster analysis, data were median centered to the group of corn oil-treated KO mice and logarithm was taken. Clustering was done using Euclidean distance with complete linkage and was performed by TIGR MeV (Version 4.6.2; The Institute for Genomic Research, Rockville, MD). Student's t-test was used for statistical analysis of BrdU and Ki-67 labeling indices and for messenger RNA (mRNA) and western blot data. Differences were considered significant when p < 0.05. Significant differences between two groups are marked by asterisks.
RESULTS

Expression of b-Catenin, CAR, and Their Targets
Consistent with previous findings (Braeuning et al., 2009 Sekine et al., 2006; Tan et al., 2006) , b-catenin was absent from hepatocytes of mice with hepatocyte-specific knockout of Ctnnb1 (in the following referred to as 'KO mice'), and the expression of known b-catenin target mRNAs was largely abolished (Supplementary Figure 1 ). Interestingly, CAR mRNA and protein levels were lowered in KO mice from both sexes, whereas expression of the CAR heterodimerization partner retinoid X receptor (RXR)a was not significantly affected ( Fig. 2A) . We have recently shown that the CAR activators TCPOBOP and PB stimulate the expression of CAR target genes in both genotypes. However, higher absolute levels of most CAR target genes were achieved in Ctnnb1 WT mice after TCPOBOP or PB treatment as compared with somewhat lower levels in KO mice (Braeuning et al., 2009) . As a representative example, Figure 2B shows Cyp2c mRNA induction by the two chemicals.
Proliferative Response to CAR Activators-Sex and Genotype Differences
The above-mentioned findings suggested that b-catenin might be required for the full response to CAR activators. We were therefore interested whether b-catenin deficiency would also affect other CAR-dependent effects, namely the induction of hepatocyte proliferation and hepatocellular hypertrophy.
Consistent with previous reports Sekine et al., 2006; Tan et al., 2006) , relative liver weight of untreated KO mice was lower than that of WT controls. It significantly increased during TCPOBOP or PB treatment in all groups, but livers from WT mice treated with CAR agonists were always significantly bigger than those from the corresponding KO mice (Fig. 2C) . The proliferative response to TCPOBOP or PB was determined by analysis of BrdU incorporation (Figs. 3A-C) and by immunostaining for the proliferation marker Ki-67 (Figs. 3B-C) . Notably, BrdU was administered continuously for 72 h during the experiment. Thus, BrdU labeling indicates the total number of hepatocytes that have undergone DNA synthesis during the experimental time period, whereas staining for Ki-67 marks only those cells which were undergoing proliferation at the time of sacrifice. As expected and consistent with published findings (Tan et al., 2006) , BrdU and Ki-67 labeling indices derived from untreated livers were consistently very low and never exceeded 1% of the hepatocytes, with a tendency for less proliferation in KO mice (data not shown). Overall, BrdU and Ki-67 labeling indices were higher in female than in male mice after administration of TCPOBOP or PB, confirming previous findings by LeddaColumbano et al. (2003) , and the response to TCPOBOP was generally somewhat higher than to PB (Figs. 3B-C) .
Previous findings have demonstrated that loss of b-catenin partially impairs liver regeneration after partial hepatectomy (Sekine et al., 2007; Tan et al., 2006) . Consistent with this, the average BrdU labeling index in male TCPOBOP-treated WT mice was significantly higher than in the TCPOBOP-treated KO group (23.7 vs. 8.4%; Fig. 3B ). A comparable statistically significant effect was also observed with PB (12.5 vs. 5.6%; Fig. 3C ). Moreover, male TCPOBOP-or PB-treated WT mice displayed a higher proportion of Ki-67-positive hepatocytes than their b-catenin-deficient counterparts (Figs. 3B-C) .
By contrast, BrdU incorporation was significantly elevated in female KO mice that were treated with TCPOBOP or PB as compared with their respective WT littermates (TCPOBOP: 65.3 vs. 45.9%; PB: 54.9 vs. 35.1%; Figs. 3B-C), thus resulting in an inversion of the pattern seen in males. Moreover, TCPOBOPtreated female KO mice showed significantly elevated Ki-67 staining (26.0 vs. 12.8%; Fig. 3C ), demonstrating that not only a higher number of cells had undergone DNA synthesis during the 72 h of the experiment but also a higher number of hepatocytes were still cycling 72 h after TCPOBOP. The mitotic index was also elevated in TCPOBOP-treated female KO mice as compared with the WT group (0.91 vs. 0.44%; p ¼ 0.006). The unexpected observation that female KO mice respond to CAR activation with higher proliferation than WT mice was verified in an independent second experiment with TCPOBOP (Supplementary Figure 2) .
The increased proliferation observed in female KO mice could have resulted from accelerated entry into S phase or from higher overall recruitment of hepatocytes into the cell cycle. To evaluate these possibilities, a kinetic analysis was carried out with KO mice, where BrdU labeling was performed during three time intervals: 0-24, 24-48, and 48-72 h after TCPOBOP. As shown in Figure 3D , no difference in BrdU incorporation was observed during the first 24 h, whereas a statistically significant elevation of BrdU incorporation in the KO mice was found between 48 and 72 h after TCPOBOP treatment (19.2 vs. 12.2%; Fig. 3D) . Accordingly, the S-phase markers proliferating cell nuclear antigen (PCNA) and Cyclin A were expressed at higher levels in female TCPOBOP-treated KO mice at the 48 and 72 h time points than in their TCPOBOP-treated WT littermates (Fig. 3E) . Figure 3A) . Proliferation was analyzed after 72 h of continuous BrdU administration via the drinking water. As expected, the BrdU labeling index of female TCPOBOP-treated WT animals was significantly lower than that of the KO group (20.6 vs. 38.2%; Fig. 3F ). Fulvestrant did not exert remarkable effects on TCPOBOP-induced BrdU incorporation in WT mice but significantly lowered BrdU incorporation in KO mice (29.2 vs. 38.2%), demonstrating that estrogen signaling is needed for the full proliferative response of the KO mice to TCPOBOP (Fig. 3F) . By contrast, treatment of male mice with the antiandrogen flutamide did not significantly alter TCPOBOP-induced proliferation in mice from either genotype (data not shown).
Differential Activation of Proliferation-Related Signaling
The transcription factor FoxM1 is involved in TCPOBOPinduced proliferation downstream of c-myc, and FoxM1 mRNA is induced upon CAR activation in mouse liver (see Introduction). In accordance with the proliferation-related parameters shown in Figures 3B and 3C , FoxM1 mRNA expression was most abundant in female TCPOBOP-treated KO mice ( Fig. 3G ; for FoxM1 protein expression, see Fig. 5E-F) . By contrast, no genotype differences in the induction of c-myc mRNA were found when comparing TCPOBOP-treated female mice (data not shown). Concomitant treatment of female KO mice with TCPOBOP and Fulvestrant led to a~30% decrease in FoxM1 expression as compared with the TCPOBOP only-treated group (Supplementary Figure 3B) , although this reduction was not statistically significant (p ¼ 0.06).
To gain further insight into signal transduction pathways which might mediate the differences in hepatocyte proliferation, liver homogenates were analyzed by a RPA approach. In total, 124 different antibodies were used, among them many were phospho-specific antibodies against signaling proteins, covering a broad spectrum of proliferation-associated pathways. Cluster analysis of the protein microarray data assigned all samples to their groups correctly with the only exception of untreated KO mice, which were correctly separated from the other groups but not perfectly separated by gender (Fig. 4) . b-Catenin, its targets glutamine synthetase and CYP2E1, and the CAR target CYP3A were among the proteins which were differentially expressed between genotypes and/or treatment groups. Complete microarray results are shown in Supplementary Table 3 .
We focused our analysis on the differences between female TCPOBOP-treated KO and WT mice. Analytes showing significant differences between these two groups are listed in Table 1 . These include not only b-catenin and its known targets but also several (phospho)-proteins engaged in mitogen-activated protein kinase (MAPK)-related signaling. Taken together, these data suggest that proliferation-stimulating MAPK signaling is more active in TCPOBOP-treated KO mice at the 72 h time point as compared with TCPOBOP-treated WT mice (Table 1) . Of note, not all of the alterations shown in the table are necessarily to be attributed directly to ongoing b-CATENIN AFFECTS CAR-DEPENDENT PROLIFERATION proliferation because effects secondary to proliferation might have been also detected. Interestingly, the latter differences in protein phosphorylation were not observed between TCPOBOPtreated male WT and KO mice. Among the proliferation-related phospho-proteins was the Ser380-phosphorylated active form of p90RSK (ribosomal S6 kinase). This is especially interesting because p90RSK activity enhances FoxM1 activity (Major et al., 2004) . We therefore verified p90RSK-pSer380 levels, as well as levels of the respective phosphorylated active forms of the p90RSK upstream activator kinases PDK1-pSer241 and pERK1/2-pThr202/Tyr204 by western blotting. Elevated levels of p90RSK-pSer380, of its activators PDK1-pSer241 and pERK1-pThr202/Tyr204, but not of pERK2-pThr202/ Tyr204 were detectable in TCPOBOP-treated female KO mice (Fig. 5 ).
DISCUSSION
We have previously shown that hepatocyte-specific knockout of b-catenin alters the induction of drug-metabolizing enzymes by CAR agonists (Braeuning et al., 2009) . The   FIG. 4 . Cluster analysis of (phospho)-protein expression in TCPOBOP-treated and control mice as determined by reverse-phase protein microarray analysis. Red color indicates high abundance of the respective protein and green color indicates low abundance. Groups of samples are defined by genotype, sex, and treatment. For detailed microarray data, see Supplementary Table 3. 118 BRAEUNING ET AL. present data demonstrate, for the first time, an influence of b-catenin on hepatocellular hyperplasia induced by the two differentially acting CAR agonists TCPOBOP and PB. Even more interesting, the data reveal a novel sex specificity of b-catenin-dependent effects: On the one hand, b-catenin KO impedes CAR-mediated proliferation in male mice, whereas it enhances the proliferative response in female mice. This contrasts the findings related to drug metabolism, where, in general, b-catenin acts as a co-stimulator of CAR-dependent effects. One might speculate that the knockout of Ctnnb1 alters the ability of CAR to dimerize with RXRa or to bind to its response elements on the DNA. However, the observation that the different outcomes of CAR signaling (i.e., induction of drug metabolism and proliferation) are regulated so differentially in female KO mice strongly suggest that CAR-dependent signaling is neither generally amplified nor generally impeded by b-catenin. The different types of CAR downstream effects have to be considered, at least in parts, independent of each other regarding their interplay with b-catenin.
The cellular context seems to be crucial for the role b-catenin plays in the modulation of CAR-dependent proliferation. Several differences between TCPOBOP-treated female WT and KO mice are described in the present paper, which converge at the level of cell cycle regulation: First, FoxM1, important for hepatocyte proliferation after CAR activation (Blanco-Bose et al., 2008) , is overexpressed in TCPOBOP-treated female KO mice. Second, blockade of estrogen signaling lowers the response to TCPOBOP in KO mice and reduces FoxM1 levels. Of note, estrogen signaling positively influences FoxM1 by different mechanisms (Karadedou, 2006; Millour et al., 2010) and induces nuclear translocation of CAR (Kawamoto et al., 2000) . The aforementioned proteins are connected through p90RSK, which boosts FoxM1 activity (Major et al., 2004) , associates with the estrogen receptor (Joel et al., 1998) , and controls the levels of the estrogen receptor co-activator Cyclin D1 (Eisinger-Mathason et al., 2010) . Activating phosphorylation of p90RSK and of the p90RSK activators PDK1 and ERK1 was indeed higher in TCPOBOPtreated female KO mice than in the respective WT group, indicating that in our system, p90RSK activation is mediated by both pathways, PI3K/PDK1 and MAPK/ERK. Recently, it has been shown that the knockout of integrinlinked kinase (ILK) induces a comparable phenotype of hepatomegaly after treatment with TCPOBOP or PB (Donthamsetty et al., 2010 (Donthamsetty et al., , 2011 . However, contrasting the situation with b-catenin KO mice, gender differences in the response of ILK knockout mice to CAR agonists were not reported. Moreover, prolonged proliferation of transgenic ILK knockout hepatocytes was connected to sustained elevated c-myc expression, which was not detectable in our analyses with b-catenin KO mice. Thus, the mechanisms by which b-catenin and ILK knockout contribute to hepatomegaly are most likely different from each other. Nonetheless, b-catenin is putatively involved in the proliferative effects caused by the knockout of ILK: After partial hepatectomy, ILK knockout mice display hepatomegaly, which is connected to elevated levels of nuclear b-catenin, indicative of an activation of b-catenin signaling in hepatectomized ILK knockout mice (Apte et al., 2009) . Thus, published data point toward a complex interplay of b-catenindependent, ILK-dependent, and CAR-dependent signaling. Signaling through b-catenin is generally considered as a stimulator of hepatocyte proliferation during liver development, regeneration, and carcinogenesis. However, there are several observations which demonstrate that activation of b-catenin signaling does not necessarily cause hepatocellular proliferation in mouse liver: (1) perivenous hepatocytes possess activated b-catenin but divide rarely (see Indroduction); (2) b-catenin activation by knockout of its negative regulator Apc induces hyperplasia only when the knockout is performed in > 70% of hepatocytes. By contrast, no proliferation is seen in single isolated Apc knockout hepatocytes (Colnot et al., 2004) ; (3) no proliferation is seen in isolated transgenic hepatocytes with activated b-catenin S33Y (unpublished data); (4) remaining WT hepatocytes in livers from b-catenin KO mice do not possess a marked proliferative advantage unless treated with PB .
Estrogen dependency of proliferation is worth being discussed in this context. Female mice generally develop less liver tumors than male mice . Moreover, it has been reported that testosterone promotes hepatocarcinogenesis , whereas this process is inhibited by ovarian hormones (Poole and Drinkwater, 1996) . Thus, the observation that the induction of proliferation caused by tumor-promoting CAR agonists such as TCPOBOP or PB is higher in female seems to be counterintuitive. The same applies to the increase in sensitivity of hepatocytes toward CAR agonists caused by estrogen signaling which was observed in our analyses. These discrepancies might be attributed to the fact that the rather acute effect of proliferation does not reflect the entire long-term process of carcinogenesis. Other effects of CAR activators have been described and may play a role in the context of liver tumor formation, for example, epigenetic changes (Phillips et al., 2007) , the disruption of intercellular communication (Kolaja et al., 2000) , and the modulation of apoptosis (Bursch et al., 2005) .
Irrespective of the underlying mechanisms, our results unveil, as yet unknown, a sex-dependent inversion of the impact of b-catenin on hepatocyte proliferation. This, in turn, suggests that additional factors modulate the cellular response to b-catenin activation and determine the proliferative outcome.
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